Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05209568 · ClinicalTrials.gov registry record · NA
Immune Responses to Gluten
A NA study of Celiac Disease and Gastrointestinal Diseases, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 2
- Study locations
NCT05209568: Recruiting NA study of Celiac Disease and Gastrointestinal Diseases, sponsored by Boston Children's Hospital.
NCT05209568 is a NA study of Celiac Disease and Gastrointestinal Diseases that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 400 participants, below the 1,963-participant average among 24 other Celiac Disease trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05209568, a NA study of Celiac Disease and Gastrointestinal Diseases, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
Primary Outcome
To determine the change in serum IL-2 level from baseline after a single oral dose of gluten
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Gluten Powder
Study Locations (2)
Colorado
- Children's Hospital Colorado - Aurora
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-01-15 |
| Est. Completion | 2029-09-30 |
| Phase | NA |
What NCT05209568 shows while recruiting
NCT05209568 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,963-participant average among 24 other Celiac Disease trials with a reported enrollment target (80% lower).
The record links to 7 conditions, with Celiac Disease appearing as the primary indexed condition, and to 1 intervention - of which Gluten Powder is the first listed.
NCT05209568 reports a single indexed study location in Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05209568 about?
NCT05209568 is a clinical study titled "Immune Responses to Gluten". This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
What is the current status of trial NCT05209568?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-01-15. Estimated completion is 2029-09-30.
What conditions does trial NCT05209568 study?
This clinical trial studies the following conditions: Celiac Disease, Gastrointestinal Diseases, Digestive System Disease, Intestinal Disease, Celiac Disease in Children.
What interventions are being tested in trial NCT05209568?
The interventions under investigation include: Gluten Powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05209568?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05209568 being conducted?
This trial has 2 study locations across Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05209568's enrollment target sits among peer trials
400 6th of 24 higher than 19 of 24 other Celiac Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Celiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
-
Gluten Technology and Education for Celiac Health
RECRUITING · NA
-
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
COMPLETED · NA
-
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
COMPLETED · NA
-
Changes in Intestinal Permeability 4 Hours After Gluten Challenge
COMPLETED · NA
-
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI